Description

Simple

Clinical

Overview

XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.

Pharmacology

Indication

Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).

Pharmacodynamic

Information currently not available.

Mechanism of action

XmAb™2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb™2513 has an XmAb™ Fc domain which increases its cytotoxic potency. XmAb™2513 recruits primary human immune cells to kill tumor cells in vitro models a... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with XmAb 2513
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with XmAb 2513.
Abituzumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with XmAb 2513.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with XmAb 2513.
Aducanumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with XmAb 2513.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XmAb 2513.
Alirocumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with XmAb 2513.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XmAb 2513.
Apolizumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Asfotase alfa.